Forcaltonin (recombinant salmon calcitonin)
- Region
- 🇪🇺 EU
- Active substance
- recombinant salmon calcitonin
- Company
- Unigene UK Ltd.
- Status
- Withdrawn
- Therapeutic area
- Hypercalcemia; Osteitis Deformans; Bone Resorption
- EU approval
- Mon 11 Jan 1999
- Application
- EMEA/H/C/000197
- ATC
- H05BA01
- Official record
- www.ema.europa.eu
Indication
Calcitonin is indicated for: Prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures Paget's disease Hypercalcaemia of malignancy
Regulatory milestones
No milestones recorded in the last year.
Follow Forcaltonin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.